Pharma needs to hedge its bets as R&D productivity declines
This article was originally published in Scrip
Executive Summary
Large pharmaceutical companies increasingly need to hedge innovation risks and enhance their reliance on R&D externalisation as they face declining in-house R&D productivity, according to a study by Mehta Partners.